Skip to main content
SpringerLink
Log in

Age and the Process of Aging

  • Chapter
  • First Online:
Developing Drug Products in an Aging Society

Part of the book series: AAPS Advances in the Pharmaceutical Sciences Series ((AAPS,volume 26))

Abstract

The epidemiological transition, with a rapid increase of the proportion of the global population aged over 65 years from 11 % in 2010 to 22 % in 2050 and about 32 % in 2100, represents a challenge for public health. More and more old persons have multimorbidities and are treated with a large number of medicines. In advanced age, the pharmacokinetics and pharmacodynamics of many drugs are altered. In addition, pharmacotherapy may be complicated by difficulties with obtaining drugs or adherence and persistence with drug regimens. Safe and effective pharmacotherapy remains one of the greatest challenges in geriatric medicine. In this chapter the process of aging is described and the influence of age on pharmacokinetics and pharmacodynamics is presented. Information needed for appropriate prescribing of medicines to older patients is provided.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lutz W, Sanderson W, Scherbov S. The coming acceleration of global population ageing. Nature 2008;451:716–9.

    Google Scholar 

  2. The world in 2100. The economist online 2011;13:48.

    Google Scholar 

  3. Active ageing, European Commission. Employment, social affairs and inclusion. 2015. http://ec.europa.eu/social/main.jsp?catId=1062&langId=en.

  4. Kirkwood T. A systematic look at an old problem. As life expectancy increases, a systems-biology approach is need to ensure that we have a healthy old age. Nature. 2008;451(7):644–7.

    Google Scholar 

  5. Kirkwood TBL. Systems biology of ageing and longevity. Philos Trans R Soc Lond B Biol Sci. 2011;366(1561):64–70.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Westendorp RGJ, Kirkwood TBL. The biology of ageing. In: Bond J, Peace SM, Dittman-Kohli, Westerhof G, editors. Ageing in society, 3th ed; 2007. p. 15–37, Sage publications (ISBN 9781412900195).

    Google Scholar 

  7. Finch CE, Tanzi RE. Genetics of aging. Science. 1997;278:407–11.

    Article  CAS  PubMed  Google Scholar 

  8. Cournil A, Kirkwood TB. If you would live long, choose your parents well. Trends Genet. 2001;17:233–5.

    Article  CAS  PubMed  Google Scholar 

  9. Kim S-H, Kaminker P, Campisi J. Telomeres, aging and cancer: in search of a happy ending. Oncogene. 2002;21(4):503–11.

    Article  CAS  Google Scholar 

  10. Cawthon RM, Smith KR, O’Brien E, Sivatchenko A, Kerber RA. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet. 2003;361(9355):393–5.

    Google Scholar 

  11. Samson MM1, Meeuwsen IB, Crowe A, Dessens JA, Duursma SA, Verhaar HJ. Relationships between physical performance measures, age, height and body weight in healthy adults. Age Ageing. 2000;29(3):235–42.

    Google Scholar 

  12. Clara Drenth-van Maanen A, Jansen PAF, Proost JH, Egberts TCG, van Zuilen AD, van der Stap D, et al. Renal function assessment in older adults. Br J Clin Pharmacol. 2013;76(4):616–23.

    Google Scholar 

  13. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49(2):M85–94.

    Article  CAS  PubMed  Google Scholar 

  14. Chiarantini D, Volpato S, Sioulis F, Bartalucci F, Del Bianco L, Mangani I, et al. Lower extremity performance measures predict long-term prognosis in older patients hospitalized for heart failure. J Card Fail. 2010;16(5):390–5.

    Article  PubMed  Google Scholar 

  15. Poortvliet RK, Blom JW, de Craen AJ, Mooijaart SP, Westendorp RG, Assendelft WJ, et al. Low blood pressure predicts increased mortality in very old age even without heart failure: the Leiden 85-plus study. Eur J Heart Fail. 2013;15(5):528–33.

    Article  PubMed  Google Scholar 

  16. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu LS, et al. on behalf of the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98.

    Google Scholar 

  17. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–30.

    Article  CAS  PubMed  Google Scholar 

  18. Warwick J, Falaschetti E, Rockwood K, Mitnitski A, Thijs L, Beckett N, et al. No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med. 2015;9(13):78.

    Article  Google Scholar 

  19. Framing Heart Study. https://www.framinghamheartstudy.org/fhsbibliography/index.php (last visited 11 June 2015).

  20. Brouwers FP, van Gilst WH, van Veldhuisen DJ. The changing face of heart failure: are we really making progress? Eur J Heart Failure. 2013;15:960–2.

    Article  Google Scholar 

  21. Huisman M, Poppelaars J, van der Horst M, Beekman ATF, Brug J, van Tilburg, et al. Cohort profile: the longitudinal aging study Amsterdam. Int J Epidemiol. 2011;40(4):868–76.

    Google Scholar 

  22. Wijnhoven HA, van Zon SK, Twisk J, Visser M. Attribution of causes of weight loss and weight gain to 3-year mortality in older adults: results from the Longitudinal Aging Study Amsterdam. J Gerontol A Biol Sci Med Sci. 2014;69(10):1236–43.

    Article  PubMed  Google Scholar 

  23. Mangoni A, Jansen P, Jackson S. Clinical pharmacology of ageing. In: Jackson S Jansen P, Mangoni A, editors. Prescribing for eldely patients. 2009. p. 1–12. Chichester, UK: Wiley-Blackwell (ISBN 9780470024287).

    Google Scholar 

  24. Jansen PAF, Brouwers JRBJ. Clinical pharmacology in old persons. Scientifica. 2012;2012(Article ID 723678):17 pages.

    Google Scholar 

  25. Gainsborough N, Maskrey V, Nelson M, Keating J, Sherwood R, Jackson S, Swift C. The association of age with gastric emptying. Age Ageing. 1993;22:37–40.

    Article  CAS  PubMed  Google Scholar 

  26. Montgomery RD, Haeney MR, Ross IN, et al. The ageing gut: a study of intestinal absorption in relation to nutrition in the elderly. Q J Med. 1978;47:97–124.

    Google Scholar 

  27. Evans MA, Broe GA, Triggs EJ, et al. Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient. Neurology. 1981;31:1288–94.

    Article  CAS  PubMed  Google Scholar 

  28. Robertson DR, Wood ND, Everest H, et al. The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. Br J Clin Pharmacol. 1989;28:61–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. McEvoy AW, Fenwick JD, Boddy K, et al. Vitamin B12 absorption from the gut does not decline with age in normal elderly humans. Age Ageing. 1982;11:180–3.

    Article  CAS  PubMed  Google Scholar 

  30. Nagayama H, Ueda M, Kumagai T, et al. Influence of ageing on the pharmacokinetics of levodopa in elderly patients with Parkinson’s disease. Parkinsonism Relat Disord. 2011;17:150–2.

    Article  PubMed  Google Scholar 

  31. Wilkinson G. The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavaialability in humans. Adv Drug Deliv Rev. 1997;27(15):129–59.

    Google Scholar 

  32. Benet L, Hoener B. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71(March):115–21.

    Article  CAS  PubMed  Google Scholar 

  33. Musteata FM. Calculation of normalized drug concentrations in the presence of altered plasma protein binding. Clin Pharmacokinet. 2012;51:55–68.

    Google Scholar 

  34. Zeeh J, Platt D. The aging liver: structural and functional changes and their consequences for drug treatment in old age. Gerontology. 2002;48:121–7.

    Google Scholar 

  35. Durnas C, Loi CM, Cusack BJ. Hepatic drug metabolism and aging. Clin Pharmacokinet. 1990;19:359–89.

    Article  CAS  PubMed  Google Scholar 

  36. Lebrun-Vignes B, Diquet B, Chosidow O. Clinical pharmacokinetics of mizolastine. Clin Pharmacokinet. 2001;40:501–7.

    Article  CAS  PubMed  Google Scholar 

  37. Sotaniemi E, Arranto A, Pelkonen O, Pasanen M. Age and cytochrome P450-linked drug metabolism in humans: an analysis of subjects with equal histopathological conditions. Clin Pharmacol Ther. 1997;61(March):331–9.

    Article  CAS  PubMed  Google Scholar 

  38. Laroche M-L, Charmes J-P. Estimation of glomerulair filtration rate in the elderly: cockcroft-gault formula versus modification of diet in renal disease formula. Pharmacotherapy. 2006;26(7):1041–46.

    Google Scholar 

  39. Pedone C, Corsonello A, Incalzi R & for the GIFA Investigators. Estimating renal function in older people: a comparison of three formulas. Age and Ageing. 2006;35:121–6.

    Google Scholar 

  40. Matsushita K, Mahmoodi BK, Woodward M, Emberson JR, Jafar TH, Jee SH, et al. for the Chronic Kidney Disease Prognosis Consortium. Comparison of risk prediction using the CKD-EPI Equation and the MDRD study equation for estimated glomerular filtration rate. J Am Med Assoc 2012;307(9):1941–51.

    Google Scholar 

  41. Bowie M, Slattum P. Pharmacodynamics in older adults: a review. The American Journal of Geriatric Pharmacotherapy. 2007;5(September):263–302.

    Article  CAS  PubMed  Google Scholar 

  42. Leendertse A, Egberts A, Stoker L & van den Bemt P. for the HARM Study group. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 2008;168(22): 1890–6.

    Google Scholar 

  43. Poli D, Antonucci E, Testa S, Tosetto A, Ageno W, Palareti G. Bleeding risk in very old patients on vitamin K antagonist treatment. Circulation. 2011;124(16): 824–9.

    Google Scholar 

  44. Bauersachs RM. Use of anticoagulants in elderly patients. Thrombosis Research. 2012;129:107–15.

    Google Scholar 

  45. Montamat S, Abernethy D. Calcium antagonists in geriatric patients: diltiazem in elderly persons with hypertension. Clin Pharmacol Ther. 1989;45:682–91.

    Article  CAS  PubMed  Google Scholar 

  46. Robin D, Hasan S, Edeki T, Lichtenstein M, Shiavi R, Wood AJ. Increased baseline sway contributes to increased losses of balance in older people following triazolam. J Am Geriatr Soc. 1996;44(March):300–4.

    Article  CAS  PubMed  Google Scholar 

  47. Albrecht S, Ihmsen H, Hering W, Geisslinger G, Dingemanse J, Schwilden H, Schuttler J. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. Clin Pharmacol Ther. 1999;65(June):630–9.

    Article  CAS  PubMed  Google Scholar 

  48. Toornvliet R, van Berckel B, Luurtsema G, Lubberink M, Geldof A, Bosch T, Oerlemans R, Lammertsma A, Franssen E. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(ll)C]verapamil and positron emission tomography. Clin Pharmacol Ther. 2006;79(June):540–8.

    Article  CAS  PubMed  Google Scholar 

  49. Kazama T, Takeuchi K, Ikeda K, Ikeda T, Kikura M, Iida T, Suzuki S, Hanai H, Sato S. Optimal propofol plasma concentration during upper gastrointestinal endoscopy in young, middle-aged, and elderly patients. Anesthesiology. 2000;93(September):662–9.

    Article  CAS  PubMed  Google Scholar 

  50. Scott J, Stanski D. Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation. The Journal of Pharmacology and Experimental Therapeutics. 1987;240(January):159–66.

    CAS  PubMed  Google Scholar 

  51. Minto C, Schnider T, Egan T, Youngs E, Lemmens H, Gambus Pedro L, Billard V, Hoke John F, Moore Katherine H, Hermann David J, Muir Keith T, Mandema J, Shafer S. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology. 1997;86:10–23.

    Google Scholar 

  52. McLachlan A, Hilmer S, Le Couteur D. Variability in response to medicines in older people: phenotypic and genotypic factors. Clin Pharmacol Ther. 2009;85(April):431–3.

    Article  CAS  PubMed  Google Scholar 

  53. Kleijer B, van Marum R, Egberts A, Jansen P, Frijters D, Heerdink E, Ribbe M. The course of behavioral problems in elderly nursing home patients with dementia when treated with antipsychotics. Int Psychogeriatr. 2009;21(October):931–40.

    Article  CAS  PubMed  Google Scholar 

  54. Knol W, van Marum RJ, Jansen PA, Egberts TC, Schobben AF. Parkinsonism in elderly users of haloperidol: associated with dose, plasma concentration, and duration of use. J Clin Psychopharmacol. 2012;32:688–93.

    Article  CAS  PubMed  Google Scholar 

  55. Miao L, Yang C, Shen Z. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: oproposal for a new dosing regimen in Chinese patients. Eur J Clinic Pharmacol. 2007;63(1):1135–41.

    Google Scholar 

  56. Beinema M, Brouwers J, Schalekamp T, Wilffert B. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost. 2008;100(December):1052–7.

    CAS  PubMed  Google Scholar 

  57. Gage B, Eby C, Johnson J, Deych E, Rieder M, Ridker P, Milligan P, Grice G, Lenzini P, Rettie A, Aquilante C, Grosso L, Marsh S, Langaee T, Farnett L, Voora D, Veenstra D, Glynn R, Barret A, McLeod H. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84(September):326–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Evans W, Mcleod H. Pharmacogenomics-drug disposition, drug targets, and side effects. N E J Med 2003;348(2):538–549.

    Google Scholar 

  59. Hilmer S, Mclachlan A, Le Couteur D. Clinical pharmacology in the geriatric patient. Fundamental Clinical Pharmacology. 2007;21(June):217–30.

    Article  CAS  PubMed  Google Scholar 

  60. Fried L, Tangen C, Walston J, Newman A, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop W, Burke G, McBurnie M. Frailty in older adults: evidence for a phenotype. J Gerontol A. Biol Sci Med Sci. 2001;56(March):M146–57.

    Article  CAS  PubMed  Google Scholar 

  61. Morgan E, Goralski K, Piquette-Miller M, Renton K, Robertson G, Chaluvadi M, Charles K, Clarke S, Kacevska M, Liddle C, Richardson T, Sharma R, Sinal C. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos. 2008;36(February):205–16.

    Article  CAS  PubMed  Google Scholar 

  62. Zahn J, Poosala S, Owen A, Ingram D, Lustig A, Carter A, Weeraratna A, Taub D, Gorospe M, Mazan-Mamczarz K, Lakatta E, Boheler K, Xu X, Mattson M, Falco G., Ko M, Schlessinger D, Firman J, Kummerfeld S, Wood W, Zonderman A, Kim S, Becker K. AGEMAP: a gene expression database for aging in mice. PLoS Genetics.2007;3:e201.

    Google Scholar 

  63. Bartlett C, Davey P, Dieppe P, Doyal L, Ebrahim S, et al. Women, older persons, and ethnic minorities: factors associated with their inclusion in randomized trials of statins 1990 to 2001. Heart. 2003;89:327–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Cherubini A, Del Signore S, Ouslander J, Semla T, Michel JP. Fighting against age discrimination in clinical trials. J Am Geriatr Soc. 2010;58:1791–6.

    Article  PubMed  Google Scholar 

  65. Dodd KS, Saczynski JS, Zhao Y, Goldberg RJ, Gurwitz JH. Exclusion of older adults and women from recent trials of acute coronary syndromes. J Am Geriatr Soc. 2011;59:506–11.

    Article  PubMed  PubMed Central  Google Scholar 

  66. McMurdo ME, Roberts H, Parker S, Wyatt N, May H, et al. Improving recruitment of older people to research through good practice. Age Ageing. 2011;40:659–65.

    Article  PubMed  Google Scholar 

  67. McMurdo ME, Witham MD, Gillespie ND. Including older people in clinical research. BMJ. 2005;331:1036–7.

    Article  PubMed  PubMed Central  Google Scholar 

  68. ICH expert working group. ICH harmonised tripartite guideline—studies in support of special population. Geriatrics. 1993;E7:2012.

    Google Scholar 

  69. Committee for medicinal products for human use (CHMP). (2010) ICH topic E7 studies in support of special populations: Geriatrics; questions and answers. 2012.

    Google Scholar 

  70. Beers E, Egberts TCG, Leufkens HGM, Jansen PAF. The views of healthcare professionals, drug developers and regulators on information about older people needed for rational drug prescription. PLoS ONE. 2013;8(8):e72060

    Google Scholar 

  71. Cerreta F, Eichler HG, Rasi G. Drug policy for an aging population—The European medicines agency’s geriatric medicines strategy. N Engl J Med. 2012;367:1972–7.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Expertise Centre Pharmacotherapy in Old Persons (Ephor), Utrecht, The Netherlands

    Paul A. F. Jansen

Authors
  1. Paul A. F. Jansen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul A. F. Jansen .

Editor information

Editors and Affiliations

  1. Graz University of Technology, Graz, Austria

    Sven Stegemann

Rights and permissions

Reprints and permissions

Copyright information

© 2016 American Association of Pharmaceutical Scientists

About this chapter

Cite this chapter

Jansen, P.A.F. (2016). Age and the Process of Aging. In: Stegemann, S. (eds) Developing Drug Products in an Aging Society. AAPS Advances in the Pharmaceutical Sciences Series, vol 26. Springer, Cham. https://doi.org/10.1007/978-3-319-43099-7_5

Download citation

Publish with us

Policies and ethics

Search

Navigation